A Decade after the Women's Health Initiative—The Experts Do Agree

Leading medical societies devoted to the care of menopausal women agree that the decision to initiate hormone therapy should be for the indication of treatment of menopauserelated symptoms.

0
0

Authors

Cynthia A. Stuenkel, M.D., N.C.M.P., Margery L. S. Gass, M.D., N.C.M.P, J. E. Manson, M.D., Dr.P.H., N.C.M.P., Rogerio A. Lobo, M.D.; Lubna Pal, M.B.B.S., M.R.C.O.G., M.Sc., N.C.M.P., Robert W. Rebar, M.D., and Janet E. Hall, M.D.

Vol 98, Issue 2, Pages 313-314

Abstract

Systemic hormone therapy is an acceptable option for relatively young women (up to age 59 years or within 10 years of menopause) and for healthy women who are bothered by moderate to severe menopausal symptoms. Individualization is key in the decision to use hormone therapy. Consideration should be given to the woman's quality-of-life priorities as well as her personal risk factors such as age, time since menopause, and her risk of blood clots, heart disease, stroke, and breast cancer.

Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00605-X/fulltext


Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.